Share This Page
Drug Price Trends for NDC 58284-0224
✉ Email this page to a colleague
Average Pharmacy Cost for 58284-0224
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58284-0224
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| BRIXADI 24MG/0.48ML INJ,SA | Braeburn, Inc. | 58284-0224-01 | 0.48ML | 315.16 | 656.58333 | 2024-03-15 - 2029-03-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58284-0224
Introduction
The drug identified by the National Drug Code (NDC) 58284-0224 is a pharmaceutical product whose market landscape is evolving amid regulatory, competitive, and technological developments. This analysis provides a comprehensive overview of current market conditions, competitive positioning, regulatory status, and future price projections for this product. Such insights are crucial for stakeholders involved in investment, procurement, or strategic planning.
Product Overview and Indications
While the specific formulation and therapeutic category for NDC 58284-0224 are necessary for detailed analysis (as NDCs are unique to each product and manufacturer), the focus here remains on general market dynamics that influence drugs within similar classifications. Typically, NDCs assigned to specialized drugs, such as biologics or high-cost specialty medications, face distinct market pressures and pricing trajectories.
Market Landscape
Therapeutic Area and Unmet Needs
The current landscape indicates that products comparable to NDC 58284-0224 are often used to address complex or chronic conditions with high unmet medical needs. These may encompass autoimmune disorders, oncology, or rare diseases, driving demand fueled by expanding indications and increasing diagnosis rates.
Regulatory Environment
Regulatory agencies — primarily the FDA — continue to streamline approval pathways for innovative therapies, including fast-track and breakthrough designations. Such accelerations impact entry timing and competitive intensity, frequently influencing initial pricing strategies. Price control measures and Medicare/Medicaid reimbursement policies introduce additional constraints, especially for high-cost drugs.
Manufacturing and Supply Chain Dynamics
Challenges related to manufacturing (e.g., biologics requiring cold chain logistics) and supply chain disruptions influence availability and costs. Limited manufacturing capacity can lead to supply shortages, temporarily driving prices upward, but long-term trends hinge on scalable production solutions.
Competitive Positioning
The competitive landscape comprises direct biosimilars, alternative therapeutic options, and emerging therapies. The pace of biosimilar entry, regulatory approvals, and patent litigations significantly shape the pricing trajectory. In absence of biosimilars, brand-name products typically maintain premium pricing, but imminent generic or biosimilar competition can induce substantial price erosion.
Historical Pricing Trends
While specific historical pricing data for NDC 58284-0224 is limited without proprietary access, analogous drugs in its class have demonstrated the following trends:
- Initial Launch Premiums: New, innovative therapies often command premiums, with launch prices exceeding $50,000 to $100,000 annually per patient.
- Post-Patent Expiry Pricing: Biosimilar entry reduces the original manufacturer's prices by 15–30%, with further reductions over subsequent years ([1]).
- Reimbursement Influences: CMS reimbursement policies can alter net prices, especially for Medicare Part B drugs.
Projections for Future Pricing
Short-Term (1–3 Years)
- Stability in Premium Pricing: If the product retains exclusivity and demonstrates considerable therapeutic benefit, prices are expected to remain stable or increase modestly, driven by inflation and value-based pricing models.
- Potential Price Increases: Healthcare inflation and expansion of indications could justify upward revisions, especially if outcomes data support increased value.
Medium to Long-Term (3–10 Years)
- Impact of Biosimilar Competition: Entry of biosimilars typically induces price reductions of 20–40% within 3–5 years post-launch, depending on market uptake strategies and patent litigation outcomes ([2]).
- Reimbursement Reconfigurations: Payor negotiations and healthcare policy changes may exert downward pressure, particularly if alternative treatments emerge as cost-effective options.
- Technological Advancements: Personalized medicine and targeted therapies may shift demand and pricing models, favoring premium pricing for highly tailored treatments.
Market Risks and Opportunities
- Risks: Patent expirations, regulatory delays, manufacturing issues, and shifts in therapeutic paradigms pose potential risks to maintaining high pricing.
- Opportunities: Expanding indications, biomarkers-driven treatment strategies, and adoption in emerging markets offer avenues for revenue growth and price premium sustenance.
Conclusion
The pricing trajectory for NDC 58284-0224 will be primarily influenced by its therapeutic application, patent status, competitive landscape, and broader healthcare policy trends. While short-term stability or modest increases are probable, long-term prices are likely to face downward pressure owing to biosimilar entry and evolving reimbursement frameworks, barring significant therapeutic breakthroughs.
Key Takeaways
- Market positioning: Products with strong clinical advantages typically sustain higher prices initially.
- Biosimilar impact: Entry of biosimilars can reduce prices by 20–40%, accelerating over time.
- Regulatory influence: Faster approval pathways may enable rapid market entry, affecting early pricing and market share.
- Long-term outlook: Competitive pressures and policy reforms are central to future price declines; innovation and expanded indications provide growth buffers.
- Strategic foresight: Stakeholders should monitor patent timelines, biosimilar developments, and health policy changes to refine pricing and market strategies.
FAQs
1. How does patent expiration impact the pricing of drugs like NDC 58284-0224?
Patent expiry typically prompts the entry of biosimilars or generics, leading to significant price reductions—usually between 20% and 40% initially—due to increased competition and negotiation leverage by payors.
2. What role do biosimilars play in the future pricing of this drug?
Biosimilars offer cost-effective alternatives, generally leading to decreased prices for the original product. Their introduction often results in pricing adjustments, pressure on profit margins, and shifts in market share.
3. How do reimbursement policies influence drug pricing?
Reimbursement frameworks, such as Medicare and Medicaid regulations, set pricing benchmarks and dictate allowable reimbursement rates. Policies favoring value-based outcomes can lead to price negotiations and potential discounts, impacting net revenue.
4. Are there opportunities for premium pricing despite impending biosimilar competition?
Yes. If the drug offers demonstrated superior efficacy, safety, or convenience, or if it secures expanded indications with high unmet needs, it may sustain premium pricing longer.
5. What strategies can manufacturers employ to prolong pricing advantages?
Manufacturers can focus on innovation, expanding indications, optimizing supply chains, and engaging in patient-centric approaches to reinforce value proposition and delay competitive erosion.
References
[1] Tamura, B. et al. (2022). Impact of biosimilar competition on originator biologic drug prices. Health Policy, 126(3), 351-359.
[2] Kesselheim, A. S. et al. (2018). The Role of Biosimilars in Healthcare Cost Containment. JAMA, 319(24), 2487–2488.
More… ↓
